<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION AND OBJECTIVES: Myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> type 1 is characterized by muscle damage and systemic manifestations, including cardiac involvement </plain></SENT>
<SENT sid="1" pm="."><plain>Our aim was to document the frequency and severity of cardiac involvement (left ventricular dysfunction and <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> or <z:e sem="disease" ids="C0264886" disease_type="Disease or Syndrome" abbrv="">conduction disorders</z:e>), the need for a pacemaker, implantable cardioverter-defibrillator, or electrophysiological study, and the development of <z:hpo ids='HP_0001699'>sudden death</z:hpo> during follow-up </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Retrospective observational study of myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> type 1 patients referred to a specialized cardiac unit </plain></SENT>
<SENT sid="3" pm="."><plain>Patients received clinical, electrocardiographic (Holter monitoring), and echocardiographic follow-up </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: We included 81 patients (51.9% men; mean age, 29.9 [14.8] years) </plain></SENT>
<SENT sid="5" pm="."><plain>The mean follow-up was 5.7 (3.9) years (range: 1-20 years) </plain></SENT>
<SENT sid="6" pm="."><plain>During this period <z:hpo ids='HP_0001688'>sinus bradycardia</z:hpo> was documented in 48.8%, PR interval≥220 ms in 31.3%, long corrected QT interval in 5%, and QRS interval≥120 ms in 7.5% </plain></SENT>
<SENT sid="7" pm="."><plain>A total of 13.8% of patients developed sinus node dysfunction, 10% of patients had <z:hpo ids='HP_0005115'>supraventricular arrhythmias</z:hpo>, 5% had <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>, and 8.8% developed second- or <z:hpo ids='HP_0001709'>third- degree atrioventricular block</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Only 1 patient had severe ventricular dysfunction </plain></SENT>
<SENT sid="9" pm="."><plain>During the follow-up, 15 pacemakers and 2 implantable cardioverter-defibrillators were implanted and 5 electrophysiological studies were performed (mainly due to <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>) </plain></SENT>
<SENT sid="10" pm="."><plain>There was only 1 <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0011675'>Arrhythmia</z:hpo> or <z:e sem="disease" ids="C0264886" disease_type="Disease or Syndrome" abbrv="">conduction disorders</z:e> are frequent during the course of myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> type 1 patients </plain></SENT>
<SENT sid="12" pm="."><plain>A significant percentage of patients require electrophysiological study and the use of a device (pacemaker or implantable cardioverter-defibrillator) </plain></SENT>
<SENT sid="13" pm="."><plain>In our experience, systolic dysfunction and <z:hpo ids='HP_0001699'>sudden death</z:hpo> are rare </plain></SENT>
<SENT sid="14" pm="."><plain>Full English text available from:www.revespcardiol.org/en </plain></SENT>
</text></document>